Clinical pharmacology of cannabinoids in early phase drug development
Zuurman, H.H.
Citation
Zuurman, H. H. (2008, May 28). Clinical pharmacology of cannabinoids in early phase drug development. Retrieved from https://hdl.handle.net/1887/12869
Version: Corrected Publisher’s Version License:
Licence agreement concerning inclusion of doctoral thesis in the Institutional
Repository of the University of Leiden
Downloaded from: https://hdl.handle.net/1887/12869
Note: To cite this publication please use the final published
version (if applicable).
stellingen behorende bij het proefschrift:
‘Clinical pharmacology of cannabinoids in early phase drug development’
Lineke Zuurman
1 Subjective effects are the most objective biomarkers to study the effects of cannabis (this thesis)
2 Progress in cannabinoid research is obstructed by an excessive variety of tests (this thesis)
3 The Volcano® vaporizer is a reproducible, practical, and well-tolerated mode of intrapulmonary thc administration with reliable pharmacokinetic and pharmacodynamic time profiles (this thesis)
4 Antagonizing thc-induced effects is a useful way to study the central nervous system effects of a cb1 antagonist (this thesis)
5 For the development of cannabinoids in general it is worthwhile to unravel the complex cardiovascular mechanisms in humans since cardiovascular side effects (tachycardia, hypotension) are a limitation for their therapeutic use (this thesis)
6 The route of administration is a decisive factor in causing unpleasant central nervous system effects by cb1/cb2 agonists (this thesis) 7 Regarding sedation and heart frequency, animal models do not
accurately predict cb1 agonist activity in humans (this thesis) 8 Cannabis research cannot bear daylight
9 Walking on the edge gives the best views and insights 10 Trying to understand the brain is a humbling experience 11 The brain is a brilliant idea
12 The truth is in the details
